Roche's Foundation Medicine wins FDA blessing for new cancer test

Roche on Monday said its Foundation Medicine unit won US Food and Drug Administration (FDA) approval for a test to help doctors understand the genetic profile of patients' tumours and guide them to effective therapies. Roche, which owns 58% of Foundation, is hoping to use the FoundationOne CDx assay to personalise cancer care, where treatment is better tailored to the specific molecular characteristics of each patient's disease.